C4 Therapeutics (C4 Therapeutics) Total Inventories : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is C4 Therapeutics Total Inventories?

C4 Therapeutics's total inventories for the quarter that ended in Mar. 2024 was $0.00 Mil. C4 Therapeutics's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. C4 Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $1.87.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. C4 Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.00.

C4 Therapeutics Total Inventories Historical Data

The historical data trend for C4 Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4 Therapeutics Total Inventories Chart

C4 Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

C4 Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

C4 Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

C4 Therapeutics (NAS:CCCC) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

C4 Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(258.192	+	0.75 * 13.599	+	0.5 * 0	-	140.089
-	0	-	0)	/	68.7786
=	1.87

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

C4 Therapeutics's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

C4 Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

C4 Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	3.039
	=	0.00

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

C4 Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of C4 Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

C4 Therapeutics (C4 Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4 Therapeutics Inc (NAS:CCCC) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472

Website

https://www.c4therapeutics.com

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

Executives

Mark Mossler	officer: Chief Accounting Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Kendra Adams	officer: Chief Financial Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Leonard Reyno	officer: Chief Medical Officer	607 NORTH LAS PALMAS AVENUE, LOS ANGELES CA 90004
Utpal Koppikar	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Donna Roy Grogan	director	1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Laura Bessen	director	4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121
Andrew Hirsch	director, officer: See Remarks	C/O BIND THERAPEUTICS, INC., 325 VASSAR ST, CAMBRIDGE MA 02139
Kelly Schick	officer: Chief People Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott N Boyle	officer: Chief Business Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Malcolm Salter	director	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Adam Crystal	officer: Chief Medical Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Elena Prokupets	director	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Jolie Siegel	officer: Chief Legal Officer	C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Stewart Fisher	officer: Chief Scientific Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Lauren White	officer: Chief Financial Officer	C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472